Detalhe da pesquisa
1.
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Haematologica
; 104(3): 576-586, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262568
2.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
J Clin Oncol
; 40(11): 1196-1205, 2022 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030036